OTCMKTS:ADOCY Adocia (ADOCY) Stock Price, News & Analysis $11.80 0.00 (0.00%) As of 09/12/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartBuy This Stock About Adocia Stock (OTCMKTS:ADOCY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Adocia alerts:Sign Up Key Stats Today's Range$11.80▼$11.8050-Day Range$11.80▼$11.8052-Week Range$9.80▼$11.80VolumeN/AAverage VolumeN/AMarket Capitalization$215.70 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Adocia is a clinical‐stage biotechnology company focused on the development of innovative formulations of therapeutic proteins for metabolic diseases, most notably diabetes. The company’s proprietary BioChaperone® platform uses small molecular excipients to stabilize and optimize the pharmacokinetic and pharmacodynamic properties of peptides and proteins. Adocia’s primary area of research centers on improving the onset, duration and patient convenience of insulin and other hormone therapies. Adocia’s pipeline includes a range of investigational products designed to address unmet needs in both type 1 and type 2 diabetes. Lead candidates feature ultra‐rapid insulin and long‐acting insulin analogs formulated to achieve faster absorption and more consistent blood glucose control. The company is also exploring combination therapies that pair insulin with other peptide hormones, as well as once‐weekly formulations of existing treatments. Clinical trials have been conducted in Europe, North America and Asia, demonstrating the platform’s versatility across multiple therapeutic areas. Founded in 2004 and headquartered in Lyon, France, Adocia leverages partnerships with global pharmaceutical companies to advance its programs toward commercialization. The company maintains a multidisciplinary team of research, regulatory and clinical experts who oversee studies in key markets worldwide. Adocia’s collaborations and licensing agreements are designed to accelerate late‐stage development, manufacture scalable drug formulations and prepare for market entry in major geographies.AI Generated. May Contain Errors. Read More Receive ADOCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adocia and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ADOCY Stock News HeadlinesAdocia raises €9.7 million in private placement, extending cash runway to Q2 2026February 26, 2025 | msn.comADOCIA Announces the Release of Its Universal Registration Document for the Year 2023April 29, 2024 | finance.yahoo.comForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW kind of AI stock. | Chaikin Analytics (Ad)ADOCIA Announces Full Year 2023 Financial Results and Provides a Corporate and Financial UpdateApril 26, 2024 | finance.yahoo.comADOCIA Announces Its Participation at Key EventsMarch 6, 2024 | finance.yahoo.comADOCIA Reports Fourth Quarter 2023 Financial Results and Provides a Business UpdateFebruary 27, 2024 | finance.yahoo.comADOCIA Announces its Financial Calendar for 2024January 25, 2024 | finance.yahoo.comADOCIA Revealed Promising Preclinical Data on AdoShell® Islets for Cell Therapy of DiabetesNovember 9, 2023 | finance.yahoo.comSee More Headlines ADOCY Stock Analysis - Frequently Asked Questions How have ADOCY shares performed this year? Adocia's stock was trading at $11.80 at the beginning of the year. Since then, ADOCY stock has increased by 0.0% and is now trading at $11.80. How do I buy shares of Adocia? Shares of ADOCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today9/15/2025Next Earnings (Estimated)9/25/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryN/A Current SymbolOTCMKTS:ADOCY CIKN/A Webwww.adocia.com Phone33-04-72-61-06-10Fax33-04-72-36-39-67Employees78Year Founded2005Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.08 Quick Ratio1.07 Sales & Book Value Annual Sales$13.12 million Price / Sales16.44 Cash FlowN/A Price / Cash FlowN/A Book Value($0.21) per share Price / Book-56.19Miscellaneous Outstanding Shares18,280,000Free FloatN/AMarket Cap$215.70 million OptionableNot Optionable Beta-0.12 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (OTCMKTS:ADOCY) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored“Godfather of AI’s” dire warningAI pioneer Geoffrey Hinton warns the technology could create massive unemployment and widen inequality, but Po...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adocia Please log in to your account or sign up in order to add this asset to your watchlist. Share Adocia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.